Real-World Outcomes of Advanced Soft Tissue Sarcoma Patients Treated with Pazopanib

Background: Pazopanib is an oral multitarget tyrosine kinase inhibitor that is currently approved for the treatment of select subtypes of advanced Soft Tissue Sarcoma (STS) in patients who have progressed on prior anthracyclinebased chemotherapy regimens. In this study, we examine data from multiple centers to assess the efficacy of pazopanib in practice outside of a clinical trial setting. Methods: A retrospective chart analysis was conducted for pre-treated, advanced soft tissue sarcoma patients who began treatment with pazopanib in Alberta, Canada and Cairo, Egypt (2012-2018). Results: In total, 39 predominantly male (56.4%) patients received pazopanib. The median age was 51, 67% of whom had an ECOG of one or less. The predominant sarcoma subtype was leiomyosarcoma (30.8%), and all patients had received at least one prior line of systemic therapy. Thirtytwo of the 39 patients (82%) were initially given the full dose of 800mg with a median time on treatment of 116 days. Seven of the 39 (18%) patients required a dose reduction while on treatment. A majority (94.9%) of patients ultimately discontinued pazopanib treatment for reasons including death (21.6%), disease progression (62.2%), and toxicity (16.4%). The median progression-free and overall survival for these patients was 4.1 months (95%CI, 3.6-4.5) and 8.4 months (95% CI, 4.3-12.5), respectively. Conclusion: Pazopanib is an efficient and generally well-tolerated oral systemic therapy for the treatment of advanced, pre-treated, non-adipocytic soft tissue sarcoma. These results show the efficacy of pazoponib outside of a clinical trial setting.

Guillain-Barre Syndrome as a Paraneoplastic Syndrome from Ewing Sarcoma

Background: Paraneoplastic syndromes have been associated with certain malignancies, classically with small cell lung cancer. However, there have been case reports of solid tumors that have been associated with paraneoplastic syndromes as well. This is believed to be the first case that details a young man with Ewing sarcoma who developed Guillain-Barre Syndrome in the form of a paraneoplastic syndrome. Case Presentation: A 23-year-old man with localized Ewing sarcoma presented to the hospital with weakness. He was initially treated with interval compressed chemotherapy and radiation, but developed recurrence and underwent hemipelvectomy. He had chronic numbness of his extremities from vincristine that felt acutely worsened over several days prior to admission. Additionally, he was now having difficulty grasping objects and walking. His exam was notable for mildly decreased strength in his lower extremities but preserved in his upper extremities along with intact extraocular movements. The following morning he was unable to move and lost all sensation in his left lower extremity along with new dysphagia. Urgent work-up revealed a normal MRI brain, MRI spine with enhancement of cauda equina nerve roots around the conus, and a lumbar puncture with cytoalbuminologic dissociation. Ultimately was diagnosed with presumed Guillain-Barre Syndrome and treated with IVIG. Conclusion: Guillain-Barre is a rare but serious syndrome that needs to be recognized quickly given its high mortality and morbidity rate and necessity of quick intervention. It is imperative for clinicians to maintain a high degree of clinical suspicion as a manifestation of paraneoplastic syndrome from malignancies.

Prosthetic Reconstruction for Proximal Tibial Osteosarcoma with an Anterolateral Surgical Approach: Case Report

Prosthetic Reconstruction for Proximal Tibial Osteosarcoma with an Anterolateral Surgical Approach: Case Report